241 related articles for article (PubMed ID: 29408808)
1. Pain control through selective chemo-axotomy of centrally projecting TRPV1+ sensory neurons.
Sapio MR; Neubert JK; LaPaglia DM; Maric D; Keller JM; Raithel SJ; Rohrs EL; Anderson EM; Butman JA; Caudle RM; Brown DC; Heiss JD; Mannes AJ; Iadarola MJ
J Clin Invest; 2018 Apr; 128(4):1657-1670. PubMed ID: 29408808
[TBL] [Abstract][Full Text] [Related]
2. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
3. Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception.
Chen SR; Pan HL
Neuropharmacology; 2008 Aug; 55(2):215-22. PubMed ID: 18579164
[TBL] [Abstract][Full Text] [Related]
4. Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.
Fukushima A; Mamada K; Iimura A; Ono H
Sci Rep; 2017 Sep; 7(1):12452. PubMed ID: 28963471
[TBL] [Abstract][Full Text] [Related]
5. Prolonged analgesic response of cornea to topical resiniferatoxin, a potent TRPV1 agonist.
Bates BD; Mitchell K; Keller JM; Chan CC; Swaim WD; Yaskovich R; Mannes AJ; Iadarola MJ
Pain; 2010 Jun; 149(3):522-528. PubMed ID: 20403666
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia.
Jeffry JA; Yu SQ; Sikand P; Parihar A; Evans MS; Premkumar LS
PLoS One; 2009 Sep; 4(9):e7021. PubMed ID: 19753113
[TBL] [Abstract][Full Text] [Related]
7. Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.
Ursu D; Knopp K; Beattie RE; Liu B; Sher E
Eur J Pharmacol; 2010 Sep; 641(2-3):114-22. PubMed ID: 20576527
[TBL] [Abstract][Full Text] [Related]
8. Antiallodynic effect of intrathecal resiniferatoxin on neuropathic pain model of chronic constriction injury.
Parisi JR; Martins de Andrade AL; Torres Silva JR; Silva ML
Acta Neurobiol Exp (Wars); 2017; 77(4):317-322. PubMed ID: 29369297
[TBL] [Abstract][Full Text] [Related]
9. Similar and different effects of capsaicin and resiniferatoxin on substance P release and transient receptor potential vanilloid type 1 expression of cultured rat dorsal root ganglion neurons.
Yang X; Gong H; Liu Z; Liu H; Wang H; Li Z
Methods Find Exp Clin Pharmacol; 2010; 32(1):3-11. PubMed ID: 20383340
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Liu BL; Cao QL; Zhao X; Liu HZ; Zhang YQ
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32960817
[TBL] [Abstract][Full Text] [Related]
11. Preservation of acute pain and efferent functions following intrathecal resiniferatoxin-induced analgesia in rats.
Bishnoi M; Bosgraaf CA; Premkumar LS
J Pain; 2011 Sep; 12(9):991-1003. PubMed ID: 21680254
[TBL] [Abstract][Full Text] [Related]
12. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.
Karai L; Brown DC; Mannes AJ; Connelly ST; Brown J; Gandal M; Wellisch OM; Neubert JK; Olah Z; Iadarola MJ
J Clin Invest; 2004 May; 113(9):1344-52. PubMed ID: 15124026
[TBL] [Abstract][Full Text] [Related]
13. Sustained inhibition of neurotransmitter release from nontransient receptor potential vanilloid type 1-expressing primary afferents by mu-opioid receptor activation-enkephalin in the spinal cord.
Zhou HY; Chen SR; Chen H; Pan HL
J Pharmacol Exp Ther; 2008 Nov; 327(2):375-82. PubMed ID: 18669865
[TBL] [Abstract][Full Text] [Related]
14. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.
Niiyama Y; Kawamata T; Yamamoto J; Omote K; Namiki A
Neuroscience; 2007 Aug; 148(2):560-72. PubMed ID: 17656027
[TBL] [Abstract][Full Text] [Related]
15. The vanilloid agonist resiniferatoxin for interventional-based pain control.
Iadarola MJ; Mannes AJ
Curr Top Med Chem; 2011; 11(17):2171-9. PubMed ID: 21671877
[TBL] [Abstract][Full Text] [Related]
16. Selective ablation of TRPV1 by intrathecal injection of resiniferatoxin in rats increases renal sympathoexcitatory responses and salt sensitivity.
Yu SQ; Ma S; Wang DH
Hypertens Res; 2018 Sep; 41(9):679-690. PubMed ID: 30006640
[TBL] [Abstract][Full Text] [Related]
17. CT-guided injection of a TRPV1 agonist around dorsal root ganglia decreases pain transmission in swine.
Brown JD; Saeed M; Do L; Braz J; Basbaum AI; Iadarola MJ; Wilson DM; Dillon WP
Sci Transl Med; 2015 Sep; 7(305):305ra145. PubMed ID: 26378245
[TBL] [Abstract][Full Text] [Related]
18. Local Resiniferatoxin Induces Long-Lasting Analgesia in a Rat Model of Full Thickness Thermal Injury.
Salas MM; Clifford JL; Hayden JR; Iadarola MJ; Averitt DL
Pain Med; 2017 Dec; 18(12):2453-2465. PubMed ID: 27794548
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain.
Brown DC; Agnello K; Iadarola MJ
Pain; 2015 Jun; 156(6):1018-1024. PubMed ID: 25659068
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals.
Cruz CD; Charrua A; Vieira E; Valente J; Avelino A; Cruz F
Exp Neurol; 2008 Dec; 214(2):301-8. PubMed ID: 18824169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
